Funding for this research was provided by:
National Institutes of Health (NS065667, NS095773)
Direction de l’hospitalisation et de l’offre de Soins (PHRC-N-PROMARA-14-09)
Received: 26 September 2019
Accepted: 9 March 2020
First Online: 17 March 2020
Ethics approval and consent to participate
: All the participants gave their written informed consent to participate in this study, which was approved by the Montpellier University Hospital’s regional Ethics Committee (number 2011-003926-028).
: Not applicable.
: Dr. Nicolas Barthélemy is a recipient of the Alzheimer’s Association Research Fellowship which supported this work. He declares that there are no conflicts of interest involved. Pr Sylvain Lehmann received institutional support from Montpellier University Hospital and the French National Research Agency for biomarker research. He received honoraria from Thermo Fisher, Roche, and Fujirebio for serving on scientific advisory boards. He is a shareholder at the Spot-to-Lab start-up company, which was not involved in this particular research. Dr. Audrey Gabelle received funds from the Fondation Philippe Chatrier. She declares that there are no conflicts of interest involved in this paper. Dr. Randall Bateman has received honoraria from Janssen, Pfizer, and Roche as a speaker; from Eisai as a consultant; and from Merck and Pfizer as an Advisory Board member. Washington University has submitted the US nonprovisional patent applications “Methods of Diagnosing and Treating Based on Site-Specific Tau Phosphorylation” (co-inventors RJB, NB) and “Central Nervous System Tau Kinetic Measurements as Diagnostic and Theragnostic Biomarkers” (co-inventors RJB, CS) and the provisional patent application “Quantification of Tau Isoforms, Modification, and Truncation for Assessment of Tauopathies” (co-inventors RJB, CS). Dr. Philippe Marin, François Becher, Christophe Hirtz, and Chihiro Sato (préciser Dr. ou Professor avant chaque nom) also declare that there are no competing interests.